Veeva Systems stock snapshot

Veeva Systems (VEEV) is back on many investors’ screens after a recent move in the share price, with the stock last closing at US$163.76 and showing mixed returns across different time frames.

The recent pullback, with a 1-day share price return of 2.34% and a year to date share price return down 25.39%, sits alongside a 1-year total shareholder return down 43.25%. This suggests that momentum has been fading despite shorter term resilience.

If you want to see how other healthcare and AI focused companies are trading, this is a good moment to scan the market using our 39 healthcare AI stocks

With Veeva Systems reporting US$3.3b in revenue and US$941.7m in net income, plus model based estimates suggesting a sizeable intrinsic discount, you have to ask: is this a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 38% Undervalued

Veeva Systems' most followed narrative pegs fair value at $262.68, well above the last close at $163.76, framing a wide valuation gap for investors to unpack.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

Curious what kind of revenue path, margin profile, and future earnings multiple need to line up to support that fair value gap and analysts' assumptions? The underlying narrative connects steady double digit growth, firm profitability targets, and a premium P/E that sits above the wider healthcare services group, all tied together using a discount rate just under 8%.

Result: Fair Value of $262.68 (UNDERVALUED)

However, you still need to weigh the risk that large pharma customers gain pricing power at renewal, and that heavy AI and product investment fails to deliver the expected payoff.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly split between recent price weakness and a bullish fair value, this is a good time to move quickly and test the thesis against the underlying numbers yourself, then see how those numbers translate into 3 key rewards

Looking for more investment ideas?

If you are serious about stress testing your view on Veeva Systems, it makes sense to stack it up against other stocks that fit clear, data driven filters.

• Spot potential bargains early by scanning our universe for companies that look mispriced on quality and fundamentals using the 47 high quality undervalued stocks.
• Anchor your portfolio with companies that carry less quantified risk by checking the 63 resilient stocks with low risk scores before volatility catches you off guard.
• Hunt for promising companies that are not widely followed yet, and see what stands out in the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.